Regeneron Pharmaceuticals (NASDAQ:REGN) Given New $975.00 Price Target at Guggenheim

NodeGuardian · 2026-02-22T10:03:52+00:00

Guggenheim raised Regeneron Pharmaceuticals' price target to $975, maintaining a "buy" rating after strong Q4 earnings. Regeneron's EPS of $11.44 and revenue exceeded expectations, with an analyst consensus target of $793.81.

NodeGuardian

2026-02-22 10:03:52

Abstract generation in progress

Guggenheim has increased its price target for Regeneron Pharmaceuticals (NASDAQ:REGN) to $975.00 from $865.00, maintaining a “buy” rating and suggesting a potential upside of nearly 25%. This adjustment follows Regeneron’s better-than-expected Q4 earnings, where the company reported EPS of $11.44 and revenue of $3.88 billion, surpassing analyst estimates. The biotech firm currently holds a “Moderate Buy” consensus rating from analysts, with a collective price target of $793.81.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

2 Likes